Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA.
Hematol Oncol Clin North Am. 2011 Aug;25(4):917-35. doi: 10.1016/j.hoc.2011.05.001.
Emerging from a largely cytokine-based era, the last several years have witnessed a dramatic change in the therapeutic landscape of renal cancer. Molecularly targeted and antiangiogenic agents now form the backbone of most therapeutic strategies for patients with advanced renal cell carcinoma (RCC). Although the next few years may not see such broad paradigm shifts, there remains significant room for improvement in the care of patients with RCC. This review discusses challenges that face physicians and researchers as well as innovations that may contribute to improving the therapeutic outcomes for patients with RCC.
从以细胞因子为基础的时代中脱颖而出，过去几年见证了肾癌治疗领域的巨大变化。分子靶向药物和抗血管生成药物现在构成了晚期肾细胞癌（RCC）患者大多数治疗策略的基础。尽管未来几年可能不会出现如此广泛的范式转变，但在 RCC 患者的治疗中仍有很大的改进空间。本文讨论了医生和研究人员面临的挑战，以及可能有助于改善 RCC 患者治疗效果的创新。
